Nuvation Bio Inc (NUVB)

Currency in USD
2.300
-0.040(-1.71%)
Closed·
After Hours
2.329+0.029(+1.27%)
·
NUVB Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
NUVB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.2902.550
52 wk Range
1.5403.455
Key Statistics
Prev. Close
2.34
Open
2.42
Day's Range
2.29-2.55
52 wk Range
1.54-3.455
Volume
4.79M
Average Volume (3m)
6.02M
1-Year Change
-20.31%
Book Value / Share
1.1
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NUVB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.167
Upside
+211.59%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Nuvation Bio Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Nuvation Bio Inc Company Profile

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.

Nuvation Bio Inc SWOT Analysis


FDA Milestone
Nuvation Bio's IBTROZI approval for ROS1-positive NSCLC marks its transition to a commercial-stage company, potentially reshaping its market position and financial outlook.
Competitive Edge
Explore IBTROZI's advantages in efficacy, brain metastasis treatment, and dosing schedule, positioning it as a potential best-in-class therapy in a competitive market.
Market Dynamics
Delve into anticipated NCCN guideline changes and increased NGS testing, which could drive higher utilization of ROS1 TKIs and expand IBTROZI's market potential.
Financial Prospects
Analysts project price targets ranging from $6 to $10, reflecting optimism about IBTROZI's commercial potential despite current stock volatility and market uncertainties.
Read full SWOT analysis

Nuvation Bio Inc Earnings Call Summary for Q2/2025

  • Q2 2025 EPS met expectations at -$0.17; revenue surpassed forecast at $4.8M vs $416,670 expected; stock rose 2.13% pre-market to $2.4
  • FDA approval of Iprozy for ROS1+ NSCLC boosted market position; 70 patients added by July-end; $607.7M cash reserves provide operational cushion
  • R&D expenses at $27.4M, SG&A at $38.5M; high expenses remain profitability concern despite strong revenue performance
  • CEO confident in Iprozy's potential as standard care for ROS1+ NSCLC; anticipates 'patient stacking phenomenon' enhancing long-term revenue
  • Future guidance cautious; negative EPS projected but potential revenue growth expected as new products gain traction
Last Updated: 07/08/2025, 15:54
Read Full Transcript

Compare NUVB to Peers and Sector

Metrics to compare
NUVB
Peers
Sector
Relationship
P/E Ratio
−3.9x16.3x−0.5x
PEG Ratio
−0.050.050.00
Price/Book
2.1x5.1x2.6x
Price / LTM Sales
54.5x1.6x3.3x
Upside (Analyst Target)
180.8%315.3%43.5%
Fair Value Upside
Unlock22.2%6.8%Unlock

Analyst Ratings

7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 7.167
(+211.59% Upside)

Earnings

Latest Release
Aug 07, 2025
EPS / Forecast
-0.17 / -0.17
Revenue / Forecast
4.83M / 416.67K
EPS Revisions
Last 90 days

NUVB Income Statement

People Also Watch

51.43
BMNR
+24.59%
3.550
ONDS
+9.23%
4.130
ATAI
-0.48%
1.950
OPEN
+5.41%
15.46
OSCR
+1.98%

FAQ

What Stock Exchange Does Nuvation Bio Trade On?

Nuvation Bio is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Nuvation Bio?

The stock symbol for Nuvation Bio is "NUVB."

What Is the Nuvation Bio Market Cap?

As of today, Nuvation Bio market cap is 782.60M.

What Is Nuvation Bio's Earnings Per Share (TTM)?

The Nuvation Bio EPS (TTM) is -0.63.

When Is the Next Nuvation Bio Earnings Date?

Nuvation Bio will release its next earnings report on 04 Nov 2025.

From a Technical Analysis Perspective, Is NUVB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Nuvation Bio Stock Split?

Nuvation Bio has split 0 times.

How Many Employees Does Nuvation Bio Have?

Nuvation Bio has 273 employees.

What is the current trading status of Nuvation Bio (NUVB)?

As of 09 Aug 2025, Nuvation Bio (NUVB) is trading at a price of 2.30, with a previous close of 2.34. The stock has fluctuated within a day range of 2.29 to 2.55, while its 52-week range spans from 1.54 to 3.46.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.